Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.amsu.2020.12.030 http://scihub22266oqcxt.onion/10.1016/j.amsu.2020.12.030 33456770!7797473!33456770     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Med+Surg+(Lond) 2021 ; 61 (ä): 122-125 Nephropedia Template TP {{tp|p=33456770|t=2021. Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis |pdf=|usr=}}{{33456770}} gab.com Text Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis JO: Ann Med Surg (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=33456770 #FOAvip The main protease (M(pro)) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important therapeutic target as it plays a major role in the processing and maturation of the viral polyprotein. GC376 is a pre-clinical dipeptide-based protease inhibitor that has been previously used for managing feline infectious peritonitis virus (FIPV). Since both GC373 and GC376 have already been successfully used in treating animal coronavirus infection, they can be considered as strong drug candidates for COVID-19 in humans. GC376 is a broad-spectrum antiviral drug that inhibits M(pro) of several viruses, including the coronaviruses like feline coronavirus, porcine epidemic diarrhoea virus, severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus, ferret, and mink coronavirus. However, further studies should be conducted to evaluate the potency, efficacy, and safety of these broad-spectrum M(pro) inhibitors in patients with COVID-19. The lessons learned from the successful use of drug candidates for treating animal coronavirus infections will help us to develop framework for their use in human trials. Twit Text FOAVip Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis ????Ann Med Surg (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=33456770 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33456770 #FOAvip English Wikipedia <ref>{{Cite pmid|33456770}}</ref> Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis #MMPMID33456770 Sharun K; Tiwari R; Dhama K Ann Med Surg (Lond) 2021[Jan]; 61 (ä): 122-125 PMID33456770show ga The main protease (M(pro)) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important therapeutic target as it plays a major role in the processing and maturation of the viral polyprotein. GC376 is a pre-clinical dipeptide-based protease inhibitor that has been previously used for managing feline infectious peritonitis virus (FIPV). Since both GC373 and GC376 have already been successfully used in treating animal coronavirus infection, they can be considered as strong drug candidates for COVID-19 in humans. GC376 is a broad-spectrum antiviral drug that inhibits M(pro) of several viruses, including the coronaviruses like feline coronavirus, porcine epidemic diarrhoea virus, severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus, ferret, and mink coronavirus. However, further studies should be conducted to evaluate the potency, efficacy, and safety of these broad-spectrum M(pro) inhibitors in patients with COVID-19. The lessons learned from the successful use of drug candidates for treating animal coronavirus infections will help us to develop framework for their use in human trials. äProtease inhibitor GC376 for COVID-19: Lessons learned from feline inf(epmc).pdf DeepDyve Pubget Overpricing